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Abstract
Background and Aims: Faecal diversion is associated with improvements in Crohn’s disease but not 
ulcerative colitis, indicating that differing mechanisms mediate the diseases. This study aimed to 
investigate levels of systemic mediators of inflammation, including fibrocytes and cytokines, [1] in 
patients with Crohn’s disease and ulcerative colitis preoperatively compared with healthy controls 
and [2] in patients with Crohn’s disease and ulcerative colitis prior to and following faecal diversion.
Methods: Blood samples were obtained from healthy individuals and patients with Crohn’s 
disease or ulcerative colitis. Levels of circulating fibrocytes were quantified using flow cytometric 
analysis and their potential relationship to risk factors of inflammatory bowel disease were 
determined. Levels of circulating cytokines involved in inflammation  and fibrocyte recruitment 
and differentiation were investigated.
Results: Circulating fibrocytes were elevated in Crohn’s disease and ulcerative colitis patients 
when compared with healthy controls. Smoking, or a history of smoking, was associated with 
increases in circulating fibrocytes in Crohn’s disease, but not ulcerative colitis. Cytokines involved 
in fibrocyte recruitment were increased in Crohn’s disease patients, whereas patients with 
ulcerative colitis displayed increased levels of pro-inflammatory cytokines. Faecal diversion in 
Crohn’s disease patients resulted in decreased circulating fibrocytes, pro-inflammatory cytokines, 
and TGF-β1, and increased IL-10, whereas the inverse was observed in ulcerative colitis patients.
Conclusions: The clinical effect of faecal diversion in Crohn’s disease and ulcerative colitis may be 
explained by differing circulating fibrocyte and cytokine responses. Such differences aid in understanding 
the disease mechanisms and suggest a new therapeutic strategy for inflammatory bowel disease.
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1. Introduction
Inflammatory bowel diseases [IBD] are chronic, relapsing, inflam-
matory conditions mediated by concerted immunological, environ-
mental, and genetic processes.1,2 They include both Crohn’s disease 
[CD] and ulcerative colitis [UC], and are believed to result from an 
overly aggressive immune response in individuals genetically suscep-
tible to an environmental factor, such as gut commensals.1,2
Faecal diversion is an approach to management of IBD patients 
whereby the stream of luminal contents is reduced or eradicated 
through the formation of an ostomy. Faecal diversion has not shown 
efficacy in the management of UC, but it has been used to great 
effect in CD.3–11 In that setting, faecal diversion is associated with 
induction of clinical remission, mucosal healing, and maintenance 
of mucosal architecture.4,7,12 The differential effect of faecal diver-
sion in CD and UC implies that patients’ microbiomes, alone or in 
combination with other faeces-borne factors, may be influential. 
We have demonstrated previously that patients with CD have a dis-
tinctly different mesenteric lymph node [MLN] microbiome com-
pared with that observed in patients with UC.13 Similarly, differences 
between the CD and UC gut microbiome have been reported.14,15 In 
summary, the MLN microbiota of CD patients is more dysregulated 
than that of UC patients when compared with the reported healthy 
gut microbiome, and reflects increases in Proteobacteria. In contrast, 
the microbiome of MLNs from UC resections exhibits similarity 
to the reported normal gut microbiome, albeit comprising elevated 
Firmicutes.13,16
MLNs are involved in the initiation and progression of im-
munological processes, which occur in response to bacterial trans-
location.17–20 The differences observed in MLN microbiomes of 
patients with CD or UC could aid in understanding the mechanisms 
mediating each disease. Specifically, Proteobacteria, encompassing 
numerous pathogenic bacteria, may trigger more aggressive im-
mune responses than bacteria present in the MLNs of UC patients. 
In contrast, MLNs from UC patients display an abundance of 
Faecalibacterium.13 Faecalibacterium is associated with anti-inflam-
matory effects and can induce IL-10 production by dendritic cells.21–
24 An influential anti-inflammatory cytokine, IL-10, can reduce 
production of pro-inflammatory cytokines while increasing levels of 
anti-inflammatory cytokines.25–27
Circulating fibrocytes have also been implicated in the patho-
genesis of IBD [in addition to inflammatory and fibrotic diseases], 
through their differentiation to fibroblasts, myofibroblasts, and 
adipocytes at sites of inflammation.28–40 These cells mediate mu-
cosal and mesenteric fibrosis and inflammation in IBD, through 
increased proliferation and cytokine and extracellular matrix pro-
duction.28,41–46 They are the cellular basis of many manifestations of 
IBD, particularly CD, including stricturing, fat wrapping, and mes-
enteric thickening.43,44,47 To our knowledge, only two studies have 
investigated circulating fibrocytes in CD, with no published litera-
ture relevant to the UC setting. In CD, levels of circulating fibrocytes 
are increased when compared with healthy controls.46,48 Recruited 
to sites of mucosal inflammation early in the inflammatory phase of 
CD,46 circulating fibrocytes are present in diseased, but not normal 
mesentery. Levels of circulating fibrocytes increase as disease se-
verity (mucosal, mesenteric, and the Crohn’s Disease Activity Index 
[CDAI]) increases,48 therefore suggesting a pathobiological role for 
fibrocytes in IBD.
Given this potential role in disease pathogenesis, we wished to 
investigate levels of circulating fibrocytes in patients with CD and, 
for the first time, UC. This study further attempted to explore the 
relationship between circulating fibrocytes and known risk factors 
of IBD. The majority of studies investigating faecal diversion in IBD 
have focused on clinical parameters and potential mucosal healing. 
However, here, faecal diversion facilitated an appraisal of systemic 
disease mechanisms and manifestations of IBD following removal 
[or considerable reduction] of the microbe-rich faecal stream, with 
emphasis on circulating fibrocytes and plasma-borne cytokines.
2. Methods
2.1. Ethical approval
Ethical approval was obtained from the Research Ethics Committee 
of University Hospital Limerick [UHL].
2.2. Inclusion criteria
All patients admitted to UHL for an operation for CD [n = 35] or 
UC [n  =  15] from March 2013 to January 2018 were included. 
Pathological controls, including patients with colorectal cancer 
[n  =  49] and patients with diverticular disease [n  =  6], and self-
declared healthy volunteers [n = 20], were recruited from UHL and 
the University of Limerick, respectively. A sub-cohort of the recruited 
patients with CD were admitted to hospital for an emergency re-
section to manage a disease-related surgical indication, such as an 
obstruction, abscess, or perforation. These patients were not suitable 
for a resection due to the extent of their disease observed at the 
time of their exploratory laparotomy, and were defunctioned with 
the creation of an ostomy to divert the faecal stream away from the 
remaining intestine, and were also included.
2.3. Faecal diversion in Crohn’s disease and 
ulcerative colitis
2.3.1. Crohn’s disease
Following admittance to hospital for an emergency resection, an ex-
ploratory laparotomy was conducted to assess the extent of disease 
in a sub-cohort of recruited patients with CD. It was determined 
that a resection which includes the mesentery,48 or a classic con-
servative resection, could not be safely or successfully completed. 
Therefore, these patients were defunctioned through the creation of 
a loop ileostomy to divert the faecal stream away from the remaining 
intestine. An average of 7.2 months later, a second exploratory lapar-
otomy was performed to once again evaluate the extent of disease. 
Here, it was decided whether to resect the diseased intestine and 
mesentery or to leave the defunctioning loop ileostomy in situ to 
allow further healing. Previous work by our group has demonstrated 
the efficacy of including the mesentery during resections for CD in 
reducing rates of surgical recurrence.48 Blood samples were taken 
from patients with CD before their initial exploration laparatomy 
with loop ileostomy creation, and again before their second explora-
tory laparotomy with or without resection [7.2 months later].
2.3.2. Ulcerative colitis
Patients with UC underwent a total colectomy followed by a comple-
tion proctectomy. An end ileostomy was created to divert the faecal 
stream away from the remaining rectum following the patient’s 
total colectomy, as per the standard of care at the Department of 
Surgery, UHL. Following an average of 13.7 months where the faecal 
stream was diverted, the end ileostomy was reversed and a com-
pletion proctectomy was performed with the formation of an ileal 
pouch-anal anastomosis. In this study, the term faecal diversion in 
patients with UC refers to the time period with the end ileostomy in 
situ [where the faecal stream was diverted away from the remaining 
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rectum]. Blood samples were taken from patients with UC before 
their total colectomy with end ileostomy creation, and again before 
their completion proctectomy [13.7 months later].
2.4. Demographics and information collected
Retrieved data included patient’s medical therapy, cigarette 
smoking status, age, and disease location and behaviour [Montreal 
classification system] at the time of their operation[s], in addition 
to their age at the time of diagnosis and a family history of IBD [if 
any].49 Preoperative white blood cell, lymphocyte, monocyte, eo-
sinophil, basophil, neutrophil, and platelet counts were obtained 
for patients in addition to their preoperative C-reactive protein 
[CRP] levels. Patient data were generated by a combination of 
direct contact, chart reviews, operation and endoscopy notes, and 
pathology reports.
2.5. Blood sample collection, preparation, and 
processing
Blood [7.5 mL] was collected from patients and healthy volun-
teers via peripheral, upper extremity venepuncture, in K3 EDTA 
S-Monovette® [Sarstedt, Nümbrecht, Germany]. The various 
components of blood, i.e., red blood cells, white blood cells, and 
plasma, were separated by density gradient centrifugation, using 
Histopaque®-1077 [Sigma-Aldrich, Wicklow, Ireland], at 1500 rpm 
for 30 min. Following separation, plasma was removed and trans-
ferred to 1.5-mL tubes for storage in 500-µL aliquots. White blood 
cells were subsequently washed in phosphate-buffered saline (PBS; 
pH 7.4 [137  mM NaCl; 2.68  mM KCl; 9.94  mM Na2HPO4; 
1.76  mM KH2PO4]) and re-suspended in freezing medium [50% 
foetal bovine serum, 40% RPMI medium, and 10% dimethyl sulph-
oxide] prior to transfer to cryogenic vials in 1-mL aliquots. Samples 
were cooled in a cryogenic temperature control rate container to 
-80 °C until processing for flow cytometry.
2.6. Flow cytometric quantification of circulating 
fibrocytes
Circulating fibrocytes were quantified as described previously.48 
Cells [1 × 106] were re-suspended in flow cytometry buffer [RPMI-
1640 medium supplemented with 10% horse serum, 0.1% so-
dium azide, and 25  mM HEPES] following thawing. Cells were 
fixed and permeabilised using BD Cytofix/Cytoperm™ solution 
[BD Biosciences, Oxford, UK] and blocked using flow cytometry 
buffer prior to intracellular staining of collagen I with mouse anti-
human Collagen-I antibody [Millipore, Cork, Ireland]. Collagen 
I was subsequently tagged with Alexa-Fluor 488 goat anti-mouse 
secondary antibody [Jackson ImmunoResearch Europe, Suffolk, 
UK]. Cells were then stained for cell surface antigen CD45 using 
PerCP anti-human CD45 [Biolegend, London, UK]. Finally, cells 
were re-suspended in micron-filtered PBS for subsequent analysis 
on a BD FACSVerse™ [BD Biosciences]. Data were analysed using 
BD FACSuite v1.0.5 [BD Biosciences] and results were displayed 
as a percentage of the total white blood cell population. A suit-
able protocol was established to detect fibrocytes by running rele-
vant controls, including fluorescence minus one controls. The 488 
blue laser was used to excite both stains, with the green detector 
reading Alexa-Fluor 488 [Ex/Em 493/519 nm] and the red detector 
reading PerCP [Ex/Em 482/667 nm]. A total of 10 000 monocyte 
cellular events were recorded with a flow rate of approximately 
0.24 µL per second. Cells were gated and those positive for CD45 
and Collagen I were regarded as fibrocytes. These markers have 
been used by several groups in identifying and quantitating fibro
cytes.36,46,50,51
2.7. Cytokine array technology to assess fold change 
in systemic inflammatory and fibrotic cytokines
Levels of 23 cytokines involved in inflammation, fibrocyte recruit-
ment, and fibrocyte differentiation were determined using RayBio® 
Human Custom Antibody Array G Series [RayBiotech, Georgia, 
USA] [Supplementary Table 1, available as Supplementary data at 
ECCO-JCC online] and compared as per manufacturer’s instruc-
tions. In brief, G Series glass slides were incubated with whole 
plasma overnight at 4°C following blocking for 30  min with 
RayBio® blocking buffer. G Series slides were then washed and in-
cubated with a custom biotinylated antibody cocktail overnight at 
4 °C. Subsequently, G Series slides were washed once again before 
incubation with IRDye 800CW Streptavidin [LI-COR Biosciences, 
UK] and visualisation on an Odyssey® SA [LI-COR]. Background 
signal was subtracted from values and data were normalised to the 
average of the positive controls within the replicate. Data were ana-
lysed as the fold change of the cytokine levels in preoperative CD or 
UC plasma when compared with the levels in healthy controls, or the 
fold change of cytokine levels in CD or UC patients following faecal 
diversion compared with the levels before faecal diversion. Levels of 
preoperative cytokines were assessed in a representative number of 
patients from our CD and UC cohorts and healthy controls. Sample 
selection was completed based on fibrocyte levels, ensuring that 
plasma from individuals with a range of fibrocyte levels was used.
2.8. Statistical analysis
Data are presented as mean ± standard error of the mean [SE] un-
less otherwise stated. All statistical analyses were completed using 
SPSSv24 [SPSS Inc., Chicago, USA]. A one-way analysis of variance 
[ANOVA] with Bonferroni post-hoc tests were used to compare the 
levels of circulating fibrocytes in patients with colorectal diseases 
and healthy controls. Two-tailed independent samples t tests were 
used to compare non-related parametric variables, and a Mann-
Whitney U test was used to compare non-related non-parametric 
variables. A  two-tailed paired t test was used to compare related 
parametric variables, and a Wilcoxon test was used to compare 
related non-parametric variables. Chi square tests and Z test for 
proportions were used to compare nominal data. A 5% level of sig-
nificance was used for all statistical tests.
3. Results
3.1. Patient and operation information
A full description of total patient demographics and operation infor-
mation is available in Table 1. Seven of the recruited patients with 
CD underwent faecal diversion. Following faecal diversion for an 
average of 7.2  months, five patients were suitable for a resection 
that included the mesentery and the formation of an anastomosis, 
and two patients had diseased intestine and mesentery which re-
mained unsuitable for a resection and the defunctioning loop ileos-
tomy was left in situ. Demographics of all patients who underwent 
faecal diversion are provided in Supplementary Table 2, available as 
Supplementary data at ECCO-JCC online.
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Table 1. Demographics of recruited patients with Crohn’s disease and ulcerative colitis.
Variable CD [n = 35] UC [n = 15] p-value
Gender   0.849 [overall chi2]
 Male 13 [37%] 6 [40%] 0.849 [Z test]
 Female 22 [63%] 9 [60%] 0.849 [Z test]
Age at operation [years] 36.9 ± 2.27 37.8 ± 3.10 0.814 [t test]
Age at diagnosis [years] 29.7 ± 2.05 35.3 ± 3.99 0.228 [t test]
Disease duration [months] 91.1 ± 16.11 63.6 ± 22.19 0.779 [t test]
Family history   0.198 [overall chi2]
 Yes 11 [31%] 3 [20%] 0.412 [Z test]
 No 17 [49%] 12 [80%] 0.039 [Z test]
 Data not available 7 [20%] 0 [0%] 0.061 [Z test]
Smoking status   0.779 [overall chi2]
 Active/history 22 [63%] 10 [59%] 0.281 [Z test]
 Non-smoker 13 [37%] 7 [41%] 0.281 [Z test] 
Operation type    
 Ileocolic resection 20 [57%] N/A N/A
 Ileocolic resection + other 1 [3%] N/A N/A
 Ileocolic resection + defunction 1 [3%] N/A N/A
 Small bowel resection 2 [6%] N/A N/A
 Sigmoid colectomy 1 [3%] N/A N/A
 Panproctocolectomy 2 [6%] N/A N/A
 Washout 1 [3%] N/A N/A
 Adhesiolysis 1 [3%] N/A N/A
 Defunction 6 [16%] N/A N/A
 Total colectomy N/A 11 [69%] N/A
 Completion proctecomy N/A 5 [31%] N/A
Medications at time of surgery 28 [80%] 13 [77%] 0.925 [overall chi2]
 Aminosalicylates 9 [26%] 7 [41%] 0.222 [chi2 test]
 Steroid 14 [40%] 6 [35%] 0.804 [chi2 test]
 Antibiotics 3 [9%] 4 [24%] 0.124 [chi2 test]
 Immunosuppressants 8 [29%] 3 [18%] 0.704 [chi2 test]
  Thiopurines 7 [20%] 3 [18%] 0.842 [z test]
  Methotrexate 1 [3%] 0 [0%] 0.484 [Z test]
 Biologics 16 [46%] 10 [59%] 0.308 [chi2 test]
  anti-TNF 15 [43%] 9 [53%] 0.497 [Z test]
  anti-α 4β 7 1 [3%] 1 [6%] 0.596 [Z test]
 None 6 [17%] 3 [18%] 0.412 [chi2 test]
 Data not available 1 [3%] 1 [6%] 0.412 [chi2 test]
Montreal Classification of disease
Age at diagnosis   0.591 [overall chi2]
 A1 ≤16 years old 2 [6%] 0 [0%] 0.347 [Z test]
 A2 = 17–40 years old 24 [69%] 8 [53%] 0.303 [Z test]
 A3 >40 years old 8 [29%] 4 [27%] 0.772 [Z test]
 Data not available 1 [3%] 1 [7%] 0.529 [Z test]
Location    
 L1 Terminal ileum 19 [54%] N/A N/A
 L2 Colonic 3 [9%] N/A N/A
 L3 Ileocolic 7 [20%] N/A N/A
 L4 Upper GI 4 [11%] N/A N/A
 L1 + L4 1 [3%] N/A N/A
 E1 proctitis N/A 1 [7%] N/A
 E2 left-sided colitis N/A 6 [40%] N/A
 E3 pan- N/A 8 [53%] N/A
 Data not available 1 [3%] N/A N/A
Disease behaviour    
 B1 non-stricturing, non-penetrating 5 [14%] N/A N/A
 B2 stricturing 14 [40%] N/A N/A
 B3 penetrating 15 [43%] N/A N/A
 P perianal involvement 3 [9%] N/A N/A
 Data not available 1 [3%] N/A N/A
Data are presented as mean ± SE. Bold text indicates statistically significant results. Italicised and underlined text indicates results for overall statistical tests. 
Biologic medication consists of anti-tumour necrosis factor [TNF] [adalimumab, infliximab, certolizumab, or golimumab] or anti-α 4β 7 integrin [vedolimumab] 
agents.
CD, Crohn’s disease; UC,ulcerative colitis; GI, gastrointestinal; N/A, not available.
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3.2. Circulating fibrocytes are elevated in 
inflammatory bowel diseases
Circulating fibrocytes were significantly elevated in patients with 
CD [n = 35] and UC [n = 17] when compared with levels in healthy 
controls [n  =  20] [CD: 8.2  ±  0.95% vs. 2.7  ±  0.34, p  =  0.005, 
Bonferroni test; UC: 8.1  ±  1.32% vs. 2.7  ±  0.34, p  =  0.037, 
Bonferroni test] [Figure 1A]. Levels of circulating fibrocytes were 
also elevated significantly in patients with colorectal cancer [n = 49] 
when compared with healthy controls [n = 20] [7.6 ± 0.96% vs. 
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Figure 1. Quantification and analysis of circulating fibrocytes in inflammatory bowel disease [IBD]. [A] Circulating fibrocytes were increased in various colorectal 
diseases when compared with healthy controls, including Crohn’s disease [CD], ulcerative colitis [UC], and colorectal cancer. Levels of circulating fibrocytes 
were elevated in patients with diverticular disease but this was not significant. [B] Circulating fibrocytes trend towards increasing in patients with CD as their 
age at the time of surgery increases. [C] Circulating fibrocytes are increased in patients with CD who smoke or with a history of smoking when compared with 
those who never smoked. Smoking has no effect on levels of circulating fibrocytes in UC patients. [D] There was a trend of increasing circulating fibrocytes as 
the age of diagnosis increased in patients with UC. [E] Levels of circulating fibrocytes are highest in patients with CD with a stricturing [B2] behaviour type. Text 
at base of bars indicates number of samples analysed [n].
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fibrocytes were elevated in patients with diverticular disease [n = 6] 
when compared with healthy controls [n = 20], this was not sig-
nificant [4.3 ± 1.13% vs. 2.7 ± 0.34%, p = 1.000, Bonferroni test]. 
However, the circulating fibrocyte level for patients with diver-
ticular disease was not reliable, due to the low number of patients 
recruited. Levels of circulating fibrocytes were similar in CD, UC, 
and colorectal cancer [Figure 1A].
The level of circulating fibrocytes in CD patients increased as 
their age at the time of surgery increased [11–20: n  =  6; 21–30: 
n = 6; 31–40: n = 9; 41–50: n = 9; 51–60: n = 4]. The same trend 
was not observed within the UC cohort [11–20: n = 0; 21–30: n = 7; 
31–40: n = 4; 41–50: n = 2; 51–60: n = 3] [Figure 1B]. Patients with 
CD who smoked and those with a history of smoking [n = 22] had 
higher levels of circulating fibrocytes compared with those who had 
never smoked [n = 13] [smoker/history of smoking vs. non-smoker: 
9.8  ± 1.28% vs. 5.7  ± 1.03%, p  =  0.017, independent samples t 
test]. Smoking had no effect on levels of circulating fibrocytes in 
patients with UC [smoker/history of smoking: n = 10; non-smoker: 
n = 7] [Figure 1C].
Circulating fibrocytes increased in patients with UC, but not CD, 
as their age at the time of diagnosis increased [UC: A2 [n = 10] vs. 
A3 [n = 4]: 6.9 ± 1.78% vs. 11.5 ± 1.18%, p = 0.053, independent 
samples t test] [Figure 1D, n located on base of bars]. There was no 
relationship between disease location at the time of operation and 
the level of circulating fibrocytes in CD [L1: n = 19; L2: n = 3; L3: 
n = 7; L4: n = 4; L1+L4: n = 1] or UC [E1: n = 1; E2: n = 8; E3: n = 8] 
[data not presented]. Patients with stricturing behavioural type [B2] 
CD [n = 14] were found to have higher levels of circulating fibrocytes 
than other CD behavioural types (i.e., inflammatory [B1] [n = 5] and 
penetrating [B3] [n = 15]) [B1: 7.0 ± 2.51%; B2: 10.4 ± 1.66%; B3: 
6.8 ± 1.24%] [Figure 1E]. Gender, family history of IBD, duration 
of disease, and perianal involvement had no effect on circulating 
fibrocyte levels in CD or UC [data not presented].
3.3. Common classes of medications used to 
manage inflammatory bowel disease have no effect 
on circulating fibrocytes in IBD
The majority of patients with CD and UC included in the study 
were undergoing medical therapy to manage disease at the time 
of surgery [Table 1]. Information on the types of medications used 
and prescribed dosage ranges is provided in Supplementary Table 
3, available as Supplementary data at ECCO-JCC online. Biologic 
agents provided to our cohort of patients comprised anti-tumour 
necrosis factor [TNF] [adalimumab, infliximab, certolizumab, 
and golimumab] and anti-integrin α 4β 7 [vedolimumab] [Table 1; 
Supplementary Table 3]. Although these are anti-inflammatory, for 
the purposes of this study we have reported their effects separately 
from non-biologic anti-inflammatory medications [e.g., mesalazine 
and sulphasalazine] [Table 1].
Medications commonly used to treat IBD had no effect on 
levels of circulating fibrocytes in CD patients [aminosalicylate: 
n = 9; steroid: n = 14; antibiotic: n = 4; immunosuppressive: n = 8; 
biologic: n  =  16] [Supplementary Figure 1A, 1B, n located on 
base of bars, available as Supplementary data at ECCO-JCC on-
line]. Similarly, antibiotics [n = 4], aminosalicylate [n = 7], steroid 
[n  =  6], and biologic [n  =  10] agents did not alter levels of cir-
culating fibrocytes in UC [Supplementary Figure 1C]. The use of 
immunosuppressive medications [n = 3] decreased levels of circu-
lating fibrocytes in UC [on immunosuppressive medications vs. not 
on immunosuppressive medications: 4.1 ± 1.77% vs. 9.6 ± 1.47%, 
p = 0.059, independent samples t test] [Supplementary Figure 1C, 
n located on base of bars, and Supplementary Table 3]. However, 
patients with UC undergoing immunosuppressive therapy were also 
administered biologic agents in combination therapeutic strategies 
[two patients on thiopurines and anti-TNF agents, one patient on 
thiopurine and an anti-α 4β 7 agent].
3.4. Cytokines associated with fibrocyte recruitment 
and differentiation are increased in Crohn’s disease 
but not ulcerative colitis
Preoperative levels of 23 plasma-borne cytokines in CD [n = 9] and 
UC [n = 7] patients were compared with their respective levels in 
healthy controls [n  =  4]. Demographics of patients whose plasma 
was used for this study are provided in Supplementary Table 4, avail-
able as Supplementary data at ECCO-JCC online.
Fibrocyte recruitment is mediated by stromal derived factor 1 
[SDF-1] (also known as C-X-C chemokine ligand 12 [CXCL12]), 
C-C ligand 5 [CCL5] (also known as regulated on activation, normal 
T cell expressed and secreted [RANTES]) and CCL24 [also known 
as Eotaxin-2].30,36,46,52,53 Levels of these cytokines were increased in 
CD, but not UC, when compared with healthy controls [Figure 2, 
associated p-values on table]. TGF-β1 was also increased in patients 
with CD [p = 0.024] but not UC. TGF-β1 mediates differentiation of 
fibrocytes to fibroblasts and myofibroblasts.29,40,54
Within various behavioural sub-types of CD (inflammatory [B1]: 
n = 1; stricturing [B2]: n = 5; penetrating [B3]: n = 3), only CCL5 
was increased in all behavioural subtypes [Supplementary Figure 
2, associated p-values in table, available as Supplementary data 
at ECCO-JCC online]. CCL24 was increased in patients with in-
flammatory and stricturing CD only [B1: p = 0.076, B2: p = 0.027]. 
Increases in SDF-1 and TGF-β1 were associated with patients with 
more complicated behavioural types of CD (SDF-1α [B2: p = 0.143, 
B3: p = 0.257]; SDF-1β [B2: p = 0.004, B3: p = 0.257]; TGF-β1 [B2: 
p = 0.043, B3: p = 0.017] [Supplementary Figure 2].
3.5. Inflammation-associated cytokines are 
increased in ulcerative colitis
Preoperative levels of cytokines associated with inflammation were 
assessed in the same cohort of CD [n = 9] and UC [n = 7] patients 
[Supplementary Table 4, available as Supplementary data at ECCO-
JCC online] and compared with their respective levels in healthy 
controls [n = 4].
UC was associated with increases in levels of pro-inflammatory 
cytokines when compared with healthy controls, including 
interleukin [IL]-6 [p  =  0.001], IL-12p40 [p  =  0.078], IL-12p70 
[p = 0.055], interferon gamma-induced protein [IP-10] [also known 
as CXCL10; p  =  0.037], interferon inducible T-cell alpha chemo-
attractant [I-TAC] [also known as CXCL11; p = 0.001], and tumour 
necrosis factor alpha [TNFα] [p = 0.001]. However, of these cyto-
kines, only IL-6 [p  =  0.096] and IP-10 [p  =  0.05] were increased 
in patients with CD and, of those, patients with a stricturing [IL-6: 
p = 0.188, IP-10: p = 0.047] or penetrating [IL-6: p = 0.021, IP-10: 
p = 0.089] behavioural type only [B2: n = 5; B3: n = 3] [Figure 2; 
Supplementary Figure 2].
Decreases in pro-inflammatory IL-16 and monocyte chemo-
attractant protein 1 [MCP-1] [also known as CCL2] were common 
to both CD and UC (CD [IL-16: p = 0.020, MCP-1: p = 0.05], UC [IL-
16: p = 0.014; MCP-1: p < 0.001]. Interestingly, anti-inflammatory 
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IL-10 was significantly increased in patients with UC [p = 0.001] but 
not CD [Figure 2].
3.6. Faecal diversion is associated with a decrease 
in fibrocytes in patients with Crohn’s disease but 
not in ulcerative colitis
Preoperative levels of circulating fibrocytes were determined in CD 
and UC patients before [CD: n = 6; UC: n = 11] and after [CD: n = 4; 
UC: n = 5] faecal diversion. Circulating fibrocytes in patients with CD 
decreased following faecal diversion [10.5 ± 2.89% vs. 2.8 ± 0.98%, 
p = 0.044, independent samples t test] [Figure 3A]. Levels of circu-
lating fibrocytes in CD patients following faecal diversion were similar 
to the levels observed in healthy controls [n = 20] [2.8 ± 0.98% vs. 
2.8 ± 0.34%, p = 0.969, independent samples t test] [Figure 3A].
In contrast, there was no difference in the percentage of circulating 
fibrocytes in patients with UC following faecal diversion [8.1 ± 1.67% 
vs. 8.7 ± 2.83%, p = 0.853, independent samples t test] [Figure 3B]. 
Following faecal diversion, levels of circulating fibrocytes in UC patients 
remained higher than those in healthy controls [n = 20] [8.7 ± 2.83% vs. 
2.7 ± 0.34%, p = 0.101, independent samples t test].
3.7. Faecal diversion is associated with changes in 
levels of haematopoietic cells and C-reactive protein 
in patients with inflammatory bowel disease
Preoperative haemotopoietic cell counts [including total white blood 
cells, lymphocytes, monocytes, eosinophils, basophils, neutrophils, 
and platelets] were available for all patients who underwent faecal 
diversion [CD: n  =  7; UC: n  =  11]. Faecal diversion was associ-
ated with decreases in monocytes, neutrophils, platelets, and total 
white blood cell count, but increases in eosinophils, in both CD and 
UC [Supplementary Figure 3, available as Supplementary data at 
ECCO-JCC online]. Notably, although both basophils and lympho-
cytes increased in patients with CD following faecal diversion, in 
patients with UC, basophils decreased and levels of lymphocytes did 
not change following faecal diversion [Supplementary Figure 3].
CRP levels were measured in patients with CD [n = 5] prior to both 
exploratory laparotomies. Levels of CRP significantly decreased in pa-
tients with CD following faecal diversion [231.6  ±  45.31  mg/mL vs. 
7.8 ± 2.87 mg/mL, p = 0.008, paired samples t test]. Similar CRP results 
were not available for patients with UC who underwent faecal diversion.
3.8. Faecal diversion results in a reduction of 
systemic inflammatory and fibrotic processes in 
Crohn’s disease but not in ulcerative colitis
Levels of post-faecal diversion plasma-borne cytokines in patients 
with CD [n = 4] and UC [n = 2] were compared with their respective 
levels in the same patients prior to faecal diversion and to levels 
in healthy controls [n = 4]. Demographics of patients who under-
went faecal diversion, whose plasma was used for this study, are 
provided in Supplementary Table 5, available as Supplementary data 
at ECCO-JCC online.
Pro-inflammatory cytokines, including IL-6 [p  =  0.012], 
IL-8 [p  =  0.064], IL-12 [p40: p  =  0.287; p70: p  =  0.162], IL-23 
[p = 0.247], and IP-10 [p = 0.331] decreased following faecal diver-
sion in patients with CD [Figure 4A]. The same cytokines increased 
following faecal diversion in patients with UC [IL-6: p = 0.452; IL-8: 
p = 0.683; IL-12, p40: p = 0.329, p70: p = 0.296; IL-23: p = 0.210; 
IP-10: p  =  0.065] [Figure 4B]. MCP-1 increased in patients with 
CD and, to a lesser extent, in UC, following faecal diversion [CD: 
p <0.001, UC: p = 0.024].
Of note, IL-10 significantly increased in patients with CD fol-
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Figure 2. Levels of circulating cytokines involved in inflammation and fibrosis in patients with inflammatory bowel disease [IBD]. The average fold change in 
cytokines in patients with Crohn’s disease [CD] and ulcerative colitis [UC] before their operation compared with levels in healthy controls. Data are presented as 
fold changes when compared with the healthy controls [data table on graph]. Solid colour bars indicate cytokines significantly different in CD or UC compared 
with healthy controls. Associated p-values are presented in the bottom table. All experiments were completed in triplicate.
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in patients with UC in the same setting [p  =  0.015] [Figure 4A, 
B]. Patients with CD displayed significantly increased [4-fold] 
levels of IL-10 following faecal diversion when compared with 
levels in healthy individuals [Supplementary Figure 4, available as 
Supplementary data at ECCO-JCC online]
Faecal diversion had no effect on levels of cytokines involved in 
fibrocyte recruitment in CD patients [Figure 4A], whereas it allowed 
increases in CCL5 [p  =  0.012], SDF-1α [p  =  0.306], and SDF-1β 
[p = 0.034] in patients with UC [Figure 4B]. TGF-β1 similarly in-
creased following faecal diversion in patients with UC [p = 0.075] 
but decreased in patients with CD [p = 0.185] [Figure 4A, B].
4. Discussion
This is the first study to investigate and quantify levels of circu-
lating fibrocytes in patients with UC [and is one of few studies 
to quantify their levels in CD] while, uniquely, determining the 
relationship between levels of circulating fibrocytes and known 
risk factors of IBD. Elevated circulating fibrocytes and distinct 
circulating cytokine profiles were associated with CD and UC 
when compared with healthy control samples. Patients with CD 
had increased levels in cytokines involved in fibrocyte recruitment 
and differentiation, whereas patients with UC displayed increased 
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Figure 3. The effect of faecal diversion on levels of circulating fibrocytes in patients with inflammatory bowel disease [IBD]. [A] Circulating fibrocytes decreased 
in patients with Crohn’s disease [CD] following faecal diversion. Levels of circulating fibrocytes were measured before the patient’s initial exploratory laparotomy 
[n = 6] and again before their second exploratory laparotomy ± resection. [B] There was no change in levels of circulating fibrocytes in patients with UC following 
faecal diversion. Circulating fibrocytes were quantified before their total colectomy, and again, before their completion proctectomy [n = 5]. Text at base of bars 
indicates number of samples analysed [n].
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It has been reported previously that circulating fibrocytes are 
elevated in patients with CD, and may have a role in its pathogen-
esis.28,46,48 We found that circulating fibrocytes are also increased 
in UC patients, suggesting a potential pathobiological role in that 
setting also. Fibrocytes, through differentiation to fibroblasts, 
myofibroblasts, and adipocytes, are capable of contributing to in-
flammation and fibrosis.28,41–46 However, although CD patients 
exhibited increases in plasma-borne cytokines associated with 
fibrocyte recruitment to sites of inflammation [e.g., CCL5, CCL24, 
and CXCL12] when compared with healthy controls, this was not 
replicated in UC patients. Therefore, although circulating fibrocytes 
are elevated in both CD and UC, it is reasonable to suggest that 
their recruitment to sites of inflammation in UC, such as the intes-
tine and mesentery, may be compromised. Our data show that levels 
of circulating fibrocytes are highest in patients with stricturing CD, 
in agreement with previous reports of fibrocyte recruitment to sites 
of mucosal inflammation early in the inflammatory phase of CD, 
where they differentiate to fibroblasts and myofibroblasts and me-
diate stricturing.43,46
In our patient cohort, smoking or a history of smoking was asso-
ciated with increased circulating fibrocytes in CD, but not UC, when 
compared with those who had never smoked. The differential effect 
of smoking in CD and UC remains to be fully elucidated. Smoking 
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Figure 4. The effect of faecal diversion on plasma-borne cytokine levels in patients with Crohn’s disease [CD] and patients with ulcerative colitis [UC]. [A] The 
average fold change in cytokines in patients with CD following faecal diversion when compared with their levels before faecal diversion. [B] The average fold 
change in cytokines in patients with UC following faecal diversion when compared with their levels before faecal diversion. All data are presented as fold 
changes when levels following faecal diversion were compared with levels before faecal diversion [data table on graph]. Solid colour bars and asterisks indicate 
cytokines significantly different in patients with CD or patients with UC following faecal diversion when compared with before faecal diversion. All experiments 
were completed in triplicate.
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patients with CD.55,56 Our data indicate that increased circulating 
fibrocytes may be implicated.
This study also represents the first time that changes in systemic 
disease mechanisms have been investigated in patients with CD or 
UC who underwent faecal diversion. Faecal diversion is associated 
with clinical remission and mucosal healing in CD, but not UC,4–7,12 
although a mechanistic basis for this remains to be determined. 
Systemic responses following diversion of the faecal stream may 
provide an explanation for its clinical differential. Despite relatively 
low numbers of patients, we observed distinctly different systemic 
responses in patients with CD when compared with those with UC, 
upon removal [or reduction] of the stream of luminal contents. In 
CD patients, faecal diversion resulted in a decrease of circulating 
fibrocytes, a reduction of pro-inflammatory cytokines and TGF-β1, 
and an increase in anti-inflammatory IL-10. Conversely, levels of cir-
culating fibrocytes did not change in UC patients following faecal 
diversion. Notably, increases were observed in pro-inflammatory 
cytokines, cytokines associated with fibrocyte recruitment and TGF-
β1, in addition to a decrease in IL-10 in patients with UC.
In health, bacteria are maintained at low levels in the MLNs by 
the host immune system,57 whereas the gut microbiota is implicated 
in restriction of translocation of pathogenic bacteria to the MLNs.58 
These defences may be compromised in IBD, particularly CD.13 The 
CD MLN microbiota reflects increases in Proteobacteria, whereas 
MLNs from UC patients have a microbiota similar to the healthy gut 
microbiome, albeit with increased Firmicutes.13,16,59,60 We have dem-
onstrated previously that the microbial profile of MLNs taken from 
the same patient was similar, irrespective of sampling location,13 
indicating that the MLN microbiome is influenced by disease rather 
than bacteria residing in the corresponding intestinal location. This 
suggests that MLN immune responses are disease-specific.
It is reasonable to suggest that the bacterial profile of MLNs from 
patients with CD or UC may influence their systemic responses. For 
instance, MLN production of TNFα in response to bacterial trans-
location has been demonstrated in a number of disease models.61–63 
IBD has been associated with increased levels of TNFα,64 where it in-
creases intestinal permeability65,66 and, in doing so, allows increased 
bacterial translocation. However, diversion of the faecal stream may 
allow clearance of bacterial DNA from the MLNs.13 Mechanistically, 
it may be that eradication of living cells or bacterial DNA from MLNs 
facilitates altered immune responses. If so, it can be postulated that 
removal of these factors from CD MLNs results in beneficial systemic 
responses for patients, with the inverse effect observed in UC. In UC 
MLNs, Firmicutes dominate, a phylum that contains numerous bac-
teria found in the healthy gut.13 Faecalibacterium are abundant in 
MLNs from UC patients.13 These bacteria exert anti-inflammatory ef-
fects and are capable of inducing dendritic cell production of IL-10.23,24 
It is possible that the removal of viable Faecalibcaterium and other 
healthy gut bacteria, and the associated eradication of bacterial DNA, 
from the intestine and MLNs could reduce levels of IL-10 and prove 
instrumental in eliciting a pro-inflammatory response in UC. 
Furthermore, MCP-1 increased following faecal diversion in pa-
tients with CD and, to a lesser extent, UC. In addition to its role as 
a chemoattractant for macrophages to sites of inflammation, MCP-1 
promotes an M2 macrophage phenotype. M2 macrophages are in-
volved in tissue repair, and MCP-1-derived M2 macrophages pro-
duce increased levels of IL-10.67 The increase of MCP-1 facilitated by 
faecal diversion may allow this shift to the M2 macrophage pheno-
type, leading to tissue repair and a reduction in pro-inflammatory 
processes. Similarly butyrate, a short-chain fatty acid [SCFA], exerts 
anti-inflammatory effects in the intestine and is produced directly 
by members of Clostridia and F. prausnitzii [both Firmicutes] or can 
be converted from other SCFAs by bifidobacteria. These bacteria, 
through their role in butyrate production, and supplementation of bu-
tyrate itself, have been suggested as therapeutic options for IBD.68–72  
Although desirable, it was not possible to assess breaches in intes-
tinal integrity by immunohistochemistry or fluorescent cell staining.
IL-10 reduces production of pro-inflammatory cytokines, while 
increasing levels of anti-inflammatory cytokines,25–27 mediating its 
potential in medical therapy for IBD. However, previous clinical 
trials assessing the effect of IL-10 supplementation in IBD have 
yielded disappointing results,73,74 and it has been postulated that ad-
ministered doses of IL-10 were too low to elicit a response.75 Our 
results suggest that IBD patients may benefit from a threshold level 
of four times the level of IL-10 present in healthy controls to in-
duce therapeutic effects. The increase of IL-10 observed in patients 
with CD correlated with a decrease in pro-inflammatory cytokines. 
Arguably, future studies investigating IL-10 therapy for IBD could 
usefully consider these threshold levels, and the balance of pro-
inflammatory cytokines relative to levels of IL-10.
In conclusion, the distinct cytokine profiles associated with CD 
and UC indicate differing mechanisms for the diseases. The nega-
tive effect of smoking observed in CD, but not UC, may be partly 
explained by increased circulating fibrocytes. Systemic responses to 
faecal diversion also differ in CD and UC. This may provide us with 
an opportunity to understand the mechanisms mediating the disease, 
including the role of the MLN microbiota. Notably, we have iden-
tified an association between clinical improvement and increased 
IL-10, further supporting the potential of IL-10 in therapy for IBD. 
As per our results, a threshold level of four times the amount of IL-10 
present in healthy individuals may be necessary to elicit a beneficial 
effect in IBD. This putative therapeutic strategy could be employed 
pragmatically by measuring levels of circulating IL-10 befor and at 
regular intervals during supplementation, in addition to monitoring 
the ratio of IL-10 to levels of pro-inflammatory cytokines.
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